Pediatrix Medical Group (NYSE:MD) Upgraded to “Buy” by Jefferies Financial Group

Jefferies Financial Group upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a research note released on Thursday morning, Marketbeat Ratings reports. The firm currently has $14.00 target price on the stock, up from their previous target price of $8.00.

A number of other research firms have also recently commented on MD. Deutsche Bank Aktiengesellschaft upgraded shares of Pediatrix Medical Group from a sell rating to a hold rating and set a $8.00 target price on the stock in a research note on Friday, June 7th. Truist Financial increased their price target on Pediatrix Medical Group from $8.00 to $10.00 and gave the stock a hold rating in a research note on Thursday, August 15th. StockNews.com upgraded Pediatrix Medical Group from a sell rating to a hold rating in a research report on Wednesday, August 7th. Finally, UBS Group lifted their target price on Pediatrix Medical Group from $9.00 to $10.50 and gave the company a neutral rating in a research note on Friday, August 9th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Pediatrix Medical Group presently has a consensus rating of Hold and a consensus price target of $10.30.

Pediatrix Medical Group Stock Down 0.9 %

MD stock opened at $11.26 on Thursday. The stock has a market capitalization of $966.90 million, a P/E ratio of -13.25, a P/E/G ratio of 1.64 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38. Pediatrix Medical Group has a 1-year low of $6.62 and a 1-year high of $13.01. The business has a fifty day moving average price of $10.04 and a 200-day moving average price of $8.88.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.03. The business had revenue of $504.30 million during the quarter, compared to analyst estimates of $505.49 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. Pediatrix Medical Group’s revenue was up .7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.37 EPS. Equities analysts forecast that Pediatrix Medical Group will post 1.19 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO C Marc Richards sold 32,562 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $10.08, for a total value of $328,224.96. Following the transaction, the chief financial officer now owns 192,785 shares of the company’s stock, valued at $1,943,272.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO C Marc Richards sold 32,562 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $10.08, for a total value of $328,224.96. Following the completion of the transaction, the chief financial officer now owns 192,785 shares of the company’s stock, valued at $1,943,272.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,100 shares of company stock valued at $701,889. 2.00% of the stock is currently owned by company insiders.

Institutional Trading of Pediatrix Medical Group

Large investors have recently bought and sold shares of the stock. Rubric Capital Management LP grew its stake in shares of Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after purchasing an additional 7,241,400 shares during the period. Invenomic Capital Management LP increased its stake in shares of Pediatrix Medical Group by 93.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,377,951 shares of the company’s stock worth $12,815,000 after purchasing an additional 664,955 shares in the last quarter. Dana Investment Advisors Inc. boosted its stake in shares of Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after acquiring an additional 455,785 shares during the last quarter. Boston Partners boosted its stake in Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after purchasing an additional 453,254 shares during the last quarter. Finally, Clark Estates Inc. NY acquired a new position in Pediatrix Medical Group during the fourth quarter worth about $3,302,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.